SAVE: Monitoring of Dialysis Vascular Accesses During Angioplasty Under Echodoppler

Sponsor
Centre Hospitalier de Vichy (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05545267
Collaborator
(none)
144
1
13.4
10.7

Study Details

Study Description

Brief Summary

Dialysis vascular accesses called arteriovenous fistulas ( AVF) are essential to ensure extra-renal purification by hemodialysis for patients with chronic end-stage renal disease. Complications of dialysis AVF cause significant morbidity and hospitalization. Dialysis AVF angioplasties are frequently used to treat stenosis, the 1st complication concerning them and which announces the complete thrombosis which may be the definitive loss of the AVF. Historically performed under X-ray, the progression in the quality of ultrasound scanners allows today to perform this procedure under echo-Doppler guidance and thus to avoid both radiation and the injection of iodinated contrast products and their complications. It is thus possible to preserve residual renal function, a situation with a better prognosis, or to help the maturation of the AVF without precipitating the patient towards dialysis. The procedure can then be less costly, requiring a much lighter infrastructure.

The complication rates of ultrasound angioplasty remain poorly known because only a few series have been published. In addition, the evolution of the echo-Doppler parameters of the AVF is unknown during angioplasty and it is difficult to know which are the most reliable to distinguish during the procedure a "good angioplasty gesture" from an incomplete angioplasty to be continued. The proposed study would provide initial insight into the question posed.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Angioplasties

Detailed Description

This is an observational, retrospective study on data from routine care. All angioplasties concerning major patients, meeting the inclusion criteria and performed during the inclusion period will be taken into account. (For this purpose, a list of procedures performed at the Vichy Hospital will be established via the angioplasty procedure reports.

In order to establish the evolution of the echographic parameters over time, the echographic data will also be collected from each follow-up report corresponding to each procedure until the end of the follow-up. These reports correspond to the normal post-intervention control ultrasounds at 1 month, 3 months and the annual visits. If intermediate ultrasounds are available, their reports will also be used.

In the case of a patient having an emergency angioplasty, the data of the control ultrasound triggering the intervention will be used as pre-intervention data.

Study Design

Study Type:
Observational
Actual Enrollment :
144 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Monitoring of Dialysis Vascular Accesses During Angioplasty Under Echodoppler (SAVE)
Actual Study Start Date :
Sep 17, 2021
Actual Primary Completion Date :
Dec 12, 2021
Anticipated Study Completion Date :
Oct 31, 2022

Outcome Measures

Primary Outcome Measures

  1. morbidity and mortality [during intervention]

    The primary outcome measure to evaluate morbidity and mortality will be the number of acute complications that occurred during the procedure and by type of complication (wall hematoma, thrombosis, rupture, spasm, injection site hematoma, pseudoaneurysm, failure)

Secondary Outcome Measures

  1. Post-angioplasty permeability [2 years]

    Post-angioplasty primary permeability, and post-angioplasty primary assisted permeability and post-angioplasty secondary permeability over the entire follow-up period

  2. Stenosis diameter [pre-intervention, immediately after the intervention, 1 month]

    Variation of the stenosis diameter

  3. Endoluminal reference diameter [pre-intervention, immediately after the intervention, 1 month]

    Variation of the endoluminal diameter

  4. Maximum systolic velocity (VSmax) [pre-intervention, immediately after the intervention, 1 month]

    Variation of the maximum systolic velocity

  5. Ratio of VSmax to upstream [pre-intervention, immediately after the intervention, 1 month]

    Varation of Ratio of VSmax to upstream

  6. End-diastolic velocity [pre-intervention, immediately after the intervention, 1 month]

    Variation of end-diastolic velocity

  7. Diameter of the anastomosis [pre-intervention, immediately after the intervention, 1 month]

    Variation of anastomosis diameter

  8. Brachial artery Maximum flow [pre-intervention, immediately after the intervention, 1 month]

    Variation of brachial artery maximum flow

  9. Brachial artery end-diastolic velocity (EDV) [pre-intervention, immediately after the intervention, 1 month]

    Varaition of Brachial artery end-diastolic velocity

  10. Brachial artery maximum systolic velocity [pre-intervention, immediately after the intervention, 1 month]

    Variation of brachial artery maximum systolic velocity

  11. Brachial artery Resistance Index [pre-intervention, immediately after the intervention, 1 month]

    Variation of brachial artery Resistance Index

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients over 18 years old

  • Patient undergoing whose fistula is treated by angioplasty under echo-doplerat the Vichy Hospital Center between 01/01/2015 and 31/12/2019

Exclusion Criteria:
  • Patients who are minors,

  • Patients with an AVF with a flow rate < 100 mL/min.

  • Patients with acute or chronic, segmental or total occlusion of an AVF segment

  • Patients with acute or chronic, segmental or total thrombosis of an AVF segment

  • Patients whose main obstacle is located on the arterial side.

  • Intervention that required the use of X-rays.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier de Vichy (CHV) Vichy France 03200

Sponsors and Collaborators

  • Centre Hospitalier de Vichy

Investigators

  • Study Director: Fabrice ABBADIE, Centre hopsitalier de Vichy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier de Vichy
ClinicalTrials.gov Identifier:
NCT05545267
Other Study ID Numbers:
  • SAVE1 - CHV 2018-2
First Posted:
Sep 19, 2022
Last Update Posted:
Sep 19, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier de Vichy
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 19, 2022